What's Happening?
Argá Medtech, a medical technology company, has announced the successful completion of enrollment for the paroxysmal atrial fibrillation (PAF) cohort in its pivotal U.S. Investigational Device Exemption (IDE) study, COHERENT-AF. This cohort includes 150
intention-to-treat subjects across 27 sites in both Europe and the United States. The COHERENT-AF study is a prospective, multicenter, non-randomized pre-market investigation designed to evaluate the safety and effectiveness of Argá Medtech's Coherent Sine Burst Electroporation (CSE) Platform in adults suffering from symptomatic, drug-refractory PAF or persistent AF (PersAF). Enrollment for the PersAF cohort is still ongoing, with completion anticipated within the next two months. The study aims to enroll up to 410 subjects in total, with 150 subjects in each of the PAF and PersAF cohorts, plus additional subjects in a second phase of the IDE investigation. All participants undergo pulmonary vein isolation (PVI) using the CSE system, with optional additional ablations performed at the operator's discretion. Each cohort's safety and effectiveness are assessed separately against predefined performance goals, with subjects being followed for 12 months.
Why It's Important?
The completion of enrollment for the PAF cohort marks a significant milestone in the development of new treatment options for atrial fibrillation, a common heart rhythm disorder. The CSE Platform, which utilizes sine wave-based pulsed field ablation (PFA), offers a single-catheter workflow that can be configured to deliver circular, linear, and focal ablation lesions. This versatility allows for the treatment of various atrial tissues, from thin-walled right ventricle to thick septal or intramural circuits, potentially streamlining procedures and improving outcomes for patients. The ability to address multiple areas without catheter exchange, as noted by Dr. Emile Daoud, Director of Electrophysiology Research at Hatton Research Institute, could be a substantial advantage in clinical settings. Successful development and regulatory approval of this technology could provide a less invasive and more efficient treatment alternative for patients who have not responded to conventional drug therapies, thereby reducing the burden of AF and improving quality of life.
What's Next?
With the PAF cohort fully enrolled, Argá Medtech will now focus on completing enrollment for the persistent AF (PersAF) cohort, which is expected within the next two months. Following the completion of enrollment for both cohorts, the company will continue to monitor subjects for 12 months to gather comprehensive safety and effectiveness data. This data will be crucial for supporting future regulatory submissions to the FDA in the United States and for CE-Mark approval in Europe. The successful outcome of the COHERENT-AF study could lead to the commercialization of the CSE Platform, making this innovative PFA technology available to a broader patient population. The company's CEO, David Neale, emphasized the commitment to generating the necessary evidence for these regulatory submissions, indicating a clear path toward bringing this new treatment to market.
